RxDoctor Payments Data

Douglas Hoff, MD

Urology · Springfield, ORNPI 1801815519

Payments from drug & device makers

$635in general payments, 2019–2025

Across 41 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$294
  • Amgen$106
  • Boston Scientific$61
  • Sumitomo Pharma America, Inc.$29
  • Endo Pharmaceuticals Inc.$26
  • Myovant Sciences Inc.$24
  • plus $97 from 8 others

What the payments were for

  • Speaking & faculty fees$10617%
  • Food & beverage$50279%
  • Education$284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635 in reported general payments places this provider in the 30th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$64,834
Medicare patients
259
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide26$360,874
NubeqaDarolutamide24$308,083
XtandiEnzalutamide12$153,233
OrgovyxRelugolix32$84,150
MyrbetriqMirabegron27$22,520
Tamsulosin Hcl175$2,959
Oxybutynin Chloride ErOxybutynin Chloride137$2,637
Trospium Chloride18$1,440
Finasteride69$970
Testosterone Cypionate15$763
Alfuzosin Hcl ErAlfuzosin Hcl22$444
Cephalexin17$316
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$294$360,87426 claims
BayerNubeqa$22$308,08324 claims
Astellas Pharma US IncXtandi, Myrbetriq$18$175,75439 claims
Sumitomo Pharma America, Inc.Orgovyx$29$84,15032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 153 urology providers in Oregon.

Other urology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →